Researchers explore the impact of different domains of sedentary behavior on an individual’s quality of life and well-being.
AstraZeneca-allied Eccogene targets early 2025 Nasdaq IPO with multiple NASH candidates
Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public offering early next year, CEO Jingye